Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?

Area of Science:

• Oncology
• Translational Science

Background:

• Epidermal growth factor receptor (EGFR) is highly expressed in head and neck squamous cell carcinoma (HNSCC).
• EGFR is a recognized therapeutic target in HNSCC.
• Current EGFR-targeting agents, apart from cetuximab, lack approved indications for HNSCC and haven't surpassed standard care efficacy.

Purpose of the Study:

• To review the clinical evidence for EGFR-targeted therapies in HNSCC.
• To discuss future directions in translational science for HNSCC treatment.
• To explore novel therapeutic strategies involving EGFR inhibitors.

Main Methods:

• Review of major clinical trial data on EGFR inhibitors in HNSCC.
• Analysis of translational research findings.
• Discussion of emerging therapeutic approaches.

Main Results:

• Several randomized trials of antibody and small molecule EGFR inhibitors have yielded disappointing results.
• No EGFR-targeting agent, besides cetuximab, has gained approval for HNSCC.
• Current agents have not shown superiority to the established standard of care.

Conclusions:

• Future strategies may involve targeting specific patient subgroups based on risk stratification.
• Inhibiting downstream or parallel signaling pathways could enhance efficacy.
• Combination therapy with immunotherapy presents a promising avenue for improving outcomes in HNSCC.